cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cti Biopharma Corp
3 watching
Current Price
$5.72
$-0.1
(-1.72%)
logo-ctic
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
725.75M
52-Week High
52-Week High
7.8
52-Week Low
52-Week Low
1.82
Average Volume
Average Volume
2.8M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization725.75M
icon52-Week High7.8
icon52-Week Low1.82
iconAverage Volume2.8M
iconDividend Yield--
iconP/E Ratio--
What does the Cti Biopharma Corp do?
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Read More
How much money does Cti Biopharma Corp make?
News & Events about Cti Biopharma Corp.
PR Newswire
5days ago
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SEATTLE, Jan. 24, 2023 SEATTLE, Jan. 24, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an...
PR Newswire
2 months ago
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope PR Newswire PALM BEACH, Fla., Dec. 1, 2022 FinancialNewsMedia.com News Commentary PALM BEACH, Fla., Dec. 1, 2022 /PRNewswire/ -- The...
Ticker Report
2 months ago
CTI BioPharma Corp. (NASDAQ:CTIC Get Rating) Investment analysts at SVB Leerink cut their FY2024 EPS estimates for CTI BioPharma in a report issued on Tuesday, November 8th. SVB Leerink analyst K. Shields now anticipates that the biopharmaceutical company will earn $0.22 per share ...
PR Newswire
4 months ago
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SEATTLE, Sept. 21, 2022 SEATTLE, Sept. 21, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced the grant of...
PR Newswire
6 months ago
CTI BioPharma to Report Second Quarter 2022 Financial Results on August 8, 2022 CTI BioPharma to Report Second Quarter 2022 Financial Results on August 8, 2022 PR Newswire SEATTLE, Aug. 1, 2022 Company Also Announces Participation in the BTIG Biotechnology Conference and the Stifel Biotech Summer...
Frequently Asked Questions
Frequently Asked Questions
What is Cti Biopharma Corp share price today?
plus_minus_icon
Can Indians buy Cti Biopharma Corp shares?
plus_minus_icon
How can I buy Cti Biopharma Corp shares from India?
plus_minus_icon
Can Fractional shares of Cti Biopharma Corp be purchased?
plus_minus_icon
What are the documents required to start investing in Cti Biopharma Corp stocks?
plus_minus_icon
What is today’s traded volume of Cti Biopharma Corp?
plus_minus_icon
What is today’s market capitalisation of Cti Biopharma Corp?
plus_minus_icon
What is the 52-Week High and Low Range of Cti Biopharma Corp?
plus_minus_icon
What percentage is Cti Biopharma Corp down from its 52-Week High?
plus_minus_icon
What percentage is Cti Biopharma Corp up from its 52-Week Low?
plus_minus_icon
Current Price
$5.72
$-0.1
(-1.72%)
logo-ctic
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00